Clinical Trial: Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC

U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07786428) titled 'Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC' on Aug. 19.

Brief Summary: The goal of this clinical trial is to compare the effectiveness of several treatment regimens for stage I triple negative breast cancer before surgery. The main question it aims to answer is if these regimens will reduce or completely remove all cancer cells before surgery.

Study Start Date: Oct. 01

Study Type: INTERVENTIONAL

Condition: Triple-Negative Breast Cancer (TNBC)

Intervention: DRUG: Pembrolizumab

Pembrolizumab 200 mg fixed dose IV once every 3 weeks

DRUG: Paclitaxel (Chemotherapy)

Paclitaxel 80 mg/m2 IV once per day on Days 1, 8, ...